Pyrrole-3-carboxamide derivatives for the treatment of obesity

Details for Australian Patent Application No. 2005214143 (hide)

Owner AstraZeneca AB

Inventors Lindstedt Alstermark, Eva-Lotte; Cheng, Leifeng; Elebring, Thomas; Bjorsne, Magnus; Boije, Anna Maria

Agent Davies Collison Cave

Pub. Number AU-B-2005214143

PCT Pub. Number WO2005/080328

Priority 0403780.0 20.02.04 GB

Filing date 17 February 2005

Wipo publication date 1 September 2005

Acceptance publication date 21 February 2008

International Classifications

C07D 207/34 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07F 7/08 (2006.01) Compounds containing elements of the 4th Group of the Periodic System

Event Publications

24 August 2006 PCT application entered the National Phase

  PCT publication WO2005/080328 Priority application(s): WO2005/080328

21 February 2008 Application Accepted

  Published as AU-B-2005214143

19 June 2008 Standard Patent Sealed

9 September 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005214146-Modulators of cannabinoid receptors

2005214141-Protein ligands for NKG2d and UL16 receptors and uses thereof